REGULATORY
Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
A Japanese health ministry panel will meet on December 2 to review Eli Lilly’s once-daily obesity drug orforglipron, known as Foundayo overseas, which would become Japan’s first oral GLP-1 receptor agonist for the condition if…

LATEST

November 19, 2026
Japan is poised to approve its first biosimilars of Daiichi Sankyo’s osteoporosis drug Pralia (denosumab), with five products waiting in the wings for simultaneous green lights in December and a potential listing next May, if…
November 19, 2026
Japan’s health ministry has suspended a drug supply monitoring system following unauthorized access that involved attempts to alter data and a possible leak of personal information belonging to pharmaceutical company representatives.The Ministry of Health, Labor…
November 19, 2026
Japanese and European pharma trade groups joined their American peer in protesting Japan’s decision to expand price cuts under its cost-effectiveness assessment (CEA) system, calling the move “deeply regrettable.”In a joint statement issued on November…

Japan’s health ministry on November 16 approved AbbVie’s glabellar lines drug Boey (trenibotulinumtoxinE), along with a slate of label expansions…

By Shinya Sato

Japan’s push to expand biosimilar use is running into a troubling supply problem. All seven ingredients that made their biosimilar…

By Kohei Hori

A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…

By Hayate Horiguchi

A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…

By Shunsuke Tani

Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA